Carcinoma of the prostate. Treating disease that has metastasized.
Common manifestations of metastatic carcinoma of the prostate are bone pain, spinal cord compression, and disseminated intravascular coagulation. Prostate-specific antigen represents a useful marker to monitor tumor progression and response to therapy. Until recently, no therapy was available to prolong survival in these patients. Now, the use of a luteinizing hormone-releasing hormone agonist (leuprolide acetate [Lupron]) plus an antiandrogen (flutamide [Eulexin]) to provide total androgen blockade has demonstrated a 25% increase in survival time.
Baum
N
N
Department of Urology, Touro Infirmary, New Orleans.
Brown
P
P
D000951:Antigens, Neoplasm / Q000302:isolation & purification; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D005485:Flutamide / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives; D006801:Humans; D016729:Leuprolide; D008297:Male; D010146:Pain / Q000532:radiotherapy; D011379:Prognosis; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D013117:Spinal Cord Compression / Q000175:diagnosis / Q000209:etiology / Q000628:therapy
D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D007987:Gonadotropin-Releasing Hormone; D005485:Flutamide; D017430:Prostate-Specific Antigen; D016729:Leuprolide